Characterization of candidate factors associated with the metastasis and progression of high-grade serous ovarian cancer DOI Creative Commons
Huiping Liu, Ling Zhou, Hongyan Cheng

et al.

Chinese Medical Journal, Journal Year: 2023, Volume and Issue: unknown

Published: June 7, 2023

Abstract Background: High-grade serous ovarian cancer (HGSOC) is the biggest cause of gynecological cancer-related mortality because its extremely metastatic nature. This study aimed to explore and evaluate characteristics candidate factors associated with metastasis progression HGSOC. Methods: Transcriptomic data HGSOC patients' samples collected from primary tumors matched omental were obtained three independent studies in National Center for Biotechnology Information (NCBI) Gene Expression Omnibus (GEO) database. Differentially expressed genes (DEGs) selected effects on prognosis using The Cancer Genome Atlas (TCGA) Hub genes' immune landscapes estimated by Tumor Immune Estimation Resource (TIMER) Finally, 25 tissues 10 normal fallopian tube tissues, immunohistochemistry (IHC) was performed quantify expression levels hub International Federation Gynecology Obstetrics (FIGO) stages. Results: Fourteen DEGs, ADIPOQ , ALPK2 BARX1 CD37 CNR2 COL5A3 FABP4 FAP GPR68 ITGBL1 MOXD1 PODNL1 SFRP2 TRAF3IP3 upregulated every database while CADPS GATA4 STAR TSPAN8 downregulated. as significantly survival recurrence. All correlated tumor microenvironment infiltration, especially cancer-associated fibroblasts natural killer (NK) cells. Furthermore, positively stage, their increased protein compared confirmed IHC ( P = 0.0002 0.0001, respectively). Conclusions: describes screening DEGs integrated bioinformatics analyses. We identified six that HGSOC, particularly which might provide effective targets predict novel insights into individual therapeutic strategies

Language: Английский

mRNA vaccine in cancer therapy: Current advance and future outlook DOI Creative Commons

Youhuai Li,

Mina Wang, Xueqiang Peng

et al.

Clinical and Translational Medicine, Journal Year: 2023, Volume and Issue: 13(8)

Published: Aug. 1, 2023

Abstract Messenger ribonucleic acid (mRNA) vaccines are a relatively new class of that have shown great promise in the immunotherapy wide variety infectious diseases and cancer. In past 2 years, SARS‐CoV‐2 mRNA contributed tremendously against SARS‐CoV2, which has prompted arrival vaccine research boom, especially cancer vaccines. Compared with conventional vaccines, significant advantages, including efficient production protective immune responses, low side effects lower cost acquisition. this review, we elaborated on development as well potential biological mechanisms latest progress various tumour treatments, discussed challenges future directions for field.

Language: Английский

Citations

74
Loss of lncRNA LINC01056 leads to sorafenib resistance in HCC DOI Creative Commons

Yau-Tuen Chan,

Junyu Wu, Yuanjun Lu

et al.

Molecular Cancer, Journal Year: 2024, Volume and Issue: 23(1)

Published: April 6, 2024

Abstract Background and aims Sorafenib is a major nonsurgical option for patients with advanced hepatocellular carcinoma (HCC); however, its clinical efficacy largely undermined by the acquisition of resistance. The aim this study was to identify key lncRNA involved in regulation sorafenib response HCC. Materials methods A clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) single-guide RNA (sgRNA) synergistic activation mediator (SAM)-pooled library applied screen regulated treatment. role identified mediating HCC examined vitro vivo. underlying mechanism delineated proteomic analysis. significance expression evaluated multiplex immunostaining on human microtissue array. Results CRISPR/Cas9 screening revealed that Linc01056 among most downregulated lncRNAs sorafenib-resistant cells. Knockdown reduced sensitivity cells sorafenib, suppressing apoptosis promoting tumour growth mice Proteomic analysis knockdown sorafenib-treated induced genes related fatty acid oxidation (FAO) while repressing glycolysis-associated genes, leading metabolic switch favouring higher intracellular energy production. FAO inhibition significantly restored sorafenib. Mechanistically, we determined PPARα critical molecule governing upon indeed, tumours Clinically, predicted optimal overall progression-free survival outcomes better response. indicated low level Conclusion Our as epigenetic regulator potential therapeutic target

Language: Английский

Citations

22
The Many Facets of PPAR-γ Agonism in Obesity and Associated Comorbidities: Benefits, Risks, Challenges, and Future Directions DOI
Dimitris Kounatidis, Natalia G. Vallianou, Eleni Rebelos

et al.

Current Obesity Reports, Journal Year: 2025, Volume and Issue: 14(1)

Published: Feb. 12, 2025

Language: Английский

Citations

2
PPAR-γ Modulators as Current and Potential Cancer Treatments DOI Creative Commons

Tiange Chi,

Mina Wang, Xu Wang

et al.

Frontiers in Oncology, Journal Year: 2021, Volume and Issue: 11

Published: Sept. 23, 2021

Worldwide, cancer has become one of the leading causes mortality. Peroxisome Proliferator-Activated Receptors (PPARs) is a family critical sensors lipids as well regulators diverse metabolic pathways. They are also equipped with capability to promote eNOS activation, regulate immunity and inflammation response. Aside from established properties, emerging discoveries made in PPAR's functions field. All considerations given, there exists great potential PPAR modulators which may hold management cancers. In particular, PPAR-γ, most expressed subtype adipose tissues two isoforms different tissue distribution, been proven be able inhibit cell proliferation, induce cycle termination apoptosis multiple cells, intercellular adhesion, cripple inflamed state tumor microenvironment, both on transcriptional protein level. However, despite multi-functionalities, safety PPAR-γ still clinical concern terms dosage, drug interactions, types stages, etc. This review aims consolidate current applications modulators, challenges applying treatment, laboratory settings. We sincerely hope provide comprehensive perspective prospect applicability field treatment.

Language: Английский

Citations

87
Deciphering the molecular pathways of saroglitazar: A dual PPAR α/γ agonist for managing metabolic NAFLD DOI
Devaraj Ezhilarasan

Metabolism, Journal Year: 2024, Volume and Issue: 155, P. 155912 - 155912

Published: April 11, 2024

Language: Английский

Citations

13
Michael Acceptors as Anti-Cancer Compounds: Coincidence or Causality? DOI Open Access
Celia María Curieses Andrés, José Manuel Pérez de la Lastra, Elena Bustamante Munguira

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(11), P. 6099 - 6099

Published: June 1, 2024

Michael acceptors represent a class of compounds with potential anti-cancer properties. They act by binding to nucleophilic sites in biological molecules, thereby disrupting cancer cell function and inducing death. This mode action, as well their ability be modified targeted, makes them promising avenue for advancing therapy. We are investigating the molecular mechanisms underlying interactions cells, particular interfere cellular processes induce apoptosis. The properties not accidental but due chemical structure reactivity. electrophilic nature these allows selectively target residues on disease-associated proteins, resulting significant therapeutic benefits minimal toxicity various diseases. opens up new perspectives development more effective precise drugs. Nevertheless, further studies essential fully understand impact our discoveries translate into clinical practice.

Language: Английский

Citations

13
PPARγ Modulators in Lung Cancer: Molecular Mechanisms, Clinical Prospects, and Challenges DOI Creative Commons
Jiyun Zhang,

Miru Tang,

Jinsai Shang

et al.

Biomolecules, Journal Year: 2024, Volume and Issue: 14(2), P. 190 - 190

Published: Feb. 4, 2024

Lung cancer is one of the most lethal malignancies worldwide. Peroxisome proliferator-activated receptor gamma (PPARγ, NR1C3) a ligand-activated transcriptional factor that governs expression genes involved in glucolipid metabolism, energy homeostasis, cell differentiation, and inflammation. Multiple studies have demonstrated PPARγ activation exerts anti-tumor effects lung through regulation lipid induction apoptosis, cycle arrest, as well inhibition invasion migration. Interestingly, may pro-tumor on cells tumor microenvironment, especially myeloid cells. Recent clinical data has substantiated potential agonists therapeutic agents for cancer. Additionally, also show synergistic with traditional chemotherapy radiotherapy. However, application remains limited due to presence adverse side effects. Thus, further research trials are necessary comprehensively explore actions both stromal evaluate vivo toxicity. This review aims consolidate molecular mechanism modulators discuss their prospects challenges tackling

Language: Английский

Citations

10
Anti-Cancer and Anti-Proliferative Potential of Cannabidiol: A Cellular and Molecular Perspective DOI Open Access
Manamele D. Mashabela, Abidemi Paul Kappo

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(11), P. 5659 - 5659

Published: May 23, 2024

Cannabinoids, the bioactive compounds found in Cannabis sativa, have been used for medicinal purposes centuries, with early discoveries dating back to BC era (BCE). However, increased recreational use of cannabis has led a negative perception its and food applications, resulting legal restrictions many regions worldwide. Recently, cannabinoids, notably Δ9-tetrahydrocannabinol (THC) cannabidiol (CBD), gained renewed interest medical field due their anti-cancer properties. These properties include inhibition tumour growth cell invasion, anti-inflammatory effects, induction autophagy apoptosis. As result, cannabinoids treat chemotherapy-associated side like nausea, vomiting, pain, increased, there suggestions implement large-scale cancer therapy. these compounds’ cellular molecular mechanisms action still need be fully understood. This review explores recent evidence CBD’s efficacy as an agent, which is non-psychoactive The current will also provide understanding common different cancers. Studies shown that activity can receptor-dependent (CB1, CB2, TRPV, PPARs) or receptor-independent induced through mechanisms, such ceramide biosynthesis, ER stress, subsequent It projected form basis therapeutic applications CBD. Therefore, it essential understand developing optimizing pre-clinical CBD-based therapies.

Language: Английский

Citations

9
Regulatory role of PPAR in colorectal cancer DOI Creative Commons
Cong Wang,

Tingcong Lv,

Binghui Jin

et al.

Cell Death Discovery, Journal Year: 2025, Volume and Issue: 11(1)

Published: Jan. 28, 2025

Language: Английский

Citations

1
Matrine protects against DSS-induced murine colitis by improving gut barrier integrity, inhibiting the PPAR-α signaling pathway, and modulating gut microbiota DOI

Huixiang Yao,

Yan Shi,

Junqing Yuan

et al.

International Immunopharmacology, Journal Year: 2021, Volume and Issue: 100, P. 108091 - 108091

Published: Aug. 30, 2021

Language: Английский

Citations

44